Zydus Wellness reports Rs 105.34 crore net loss in Q2

Published On 2020-11-03 05:30 GMT | Update On 2020-11-03 12:27 GMT

New Delhi: Zydus Wellness on Monday reported widening of its consolidated net loss to Rs 105.34 crore for the quarter ended on September 30, 2020, from that of Rs 12.02 crore in the year-ago period. Total income stood at Rs 344.80 crore for the reported quarter, up 4.49 percent compared to Rs 329.98 crore for the same period a year ago, Zydus Wellness said in a BSE filing.

During the quarter under review, Zydus Wellness reported exceptional expenses of Rs 97.95 crore against Rs 10.05 crore in the same period a year ago. "In the process of integration and concluding the merger of the acquired entity, the company incurred various expenses towards transition service agreement (TSA), consultancy fees, stamp duties, legal and professional charges and other incidental charges.

"The company would not have incurred these expenses in the normal course of business and hence these expenses are classified as exceptional items for the quarter and six months ended September 30, 2019, and year ended March 31, 2020," the company said.

Zydus Wellness said the secured non-convertible debentures (NCDs) that were previously issued by the company have been purchased by its subsidiary company from the market aggregating to Rs 1,10,500 lakh during the quarter ending September 30, 2020 and are held by the subsidiary company as of September 30, 2020. Exceptional expenses also includes the premium amount paid towards purchase of the non-convertible debentures by its subsidiary company.

Zydus Wellness said during the quarter gone by, its key brands namely, Sugar Free, Everyuth Scrub and Everyuth Peel Off, Glucon D and Nycil continued to hold strong positions in their respective categories. The company continued to grow the categories and increase market share of its brands with new offerings and expanding its reach through e-commerce channels and building brand advocacy, during the quarter, it added.

Read also: Zydus Wellness raises Rs 650 crores via qualified institutional buyers route

Article Source : PTI

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Ruchika Sharma

Ruchika Sharma joined Medical Dialogue as an Correspondent for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751

Comments Policy

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Zydus Wellness reports Rs 105.34 crore net loss in Q2

Similar News

Shilpa Pharma Lifesciences Unit-1 successfully completes GMP inspection from Brazilian regulatory authority

Lupin rolls out Nasal spray for rhinorrhea relief in US

Pfizer Told To Conduct Phase IV Trial of Abrocitinib in Indian Adolescents with Atopic Dermatitis

CBI Cracks Down on PCI Chief Montu Patel in College Bribery Scandal

Submit Full Adverse Event Data from Lenvatinib Phase IV Liver Cancer Trial: CDSCO Panel To Eisai Pharma

Over 700 bottles of Codeine Cough Syrup seized, 2 arrested

Massive Rs 1.2 crore Oxytocin seizure in Lucknow, 3 held

High-Alcohol Medicinal Preparations to Come Under Schedule H1: Govt Panel Approves Rule Change